NCT02972840 2026-02-18
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV
Phase 3 Active not recruiting
Acerta Pharma BV
Celgene
Genmab
Eli Lilly and Company
Checkpoint Therapeutics, Inc.